Ameloblastin Inhibitors
Ameloblastin inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of ameloblastin, a critical extracellular matrix protein involved in the development and mineralization of enamel, the hard, protective outer layer of teeth. Ameloblastin, also known as AMBN or sheathlin, is produced by ameloblasts, the cells responsible for enamel formation during tooth development. It plays a crucial role in regulating the adhesion, proliferation, and differentiation of ameloblasts, as well as in guiding the proper organization and alignment of enamel crystals. This protein interacts with other enamel matrix proteins, such as amelogenin and enamelin, to ensure the orderly deposition and maturation of enamel, contributing to the hardness and durability of teeth. By inhibiting ameloblastin, researchers can disrupt these processes, offering a valuable tool to study the specific roles of ameloblastin in enamel biomineralization and tooth development.
In research settings, ameloblastin inhibitors are instrumental in exploring the molecular mechanisms underlying enamel formation and the broader implications of enamel matrix protein interactions on dental tissue development. By blocking ameloblastin activity, scientists can investigate how the inhibition affects the behavior of ameloblasts, including their ability to proliferate, migrate, and secrete enamel matrix components. This inhibition allows researchers to study the impact on enamel structure, particularly focusing on the organization and mineralization of enamel crystals, and how these processes contribute to the overall strength and integrity of the tooth. Additionally, ameloblastin inhibitors provide insights into the interactions between ameloblastin and other matrix proteins, shedding light on the complex regulatory networks that control enamel formation and the maintenance of dental health. Through these studies, the use of ameloblastin inhibitors enhances our understanding of the critical processes involved in tooth development, the regulation of enamel biomineralization, and the broader implications of these processes for dental biology and oral health.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin is a direct inhibitor of Ameloblastin, disrupting N-glycosylation processes. Its inhibition of N-glycosylation negatively affects Ameloblastin function, leading to altered cellular interactions and potential impairment of enamel formation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is a direct inhibitor of Ameloblastin, interfering with protein transport from the endoplasmic reticulum to the Golgi apparatus. By disrupting intracellular trafficking, Brefeldin A hinders proper localization and function of Ameloblastin, potentially impacting enamel formation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a direct inhibitor of Ameloblastin, targeting phosphoinositide 3-kinases (PI3Ks). Inhibition of PI3Ks by Wortmannin disrupts downstream signaling pathways involved in Ameloblastin function, potentially affecting enamel formation and cellular interactions. | ||||||
TAK 632 | 1228591-30-7 | sc-473801 | 5 mg | $228.00 | ||
TAK-632 is a direct inhibitor of Ameloblastin, specifically targeting the mitogen-activated protein kinase kinase 1 (MEK1). By inhibiting MEK1, TAK-632 disrupts the MAPK pathway, affecting Ameloblastin function and potentially influencing enamel formation and cellular interactions. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI is a direct inhibitor of Ameloblastin, acting as a glycogen synthase kinase-3 (GSK-3) inhibitor. Inhibition of GSK-3 by CHIR-99021 influences downstream signaling pathways related to Ameloblastin function, potentially impacting enamel formation and cellular interactions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a direct inhibitor of Ameloblastin, targeting c-Jun N-terminal kinase (JNK) signaling. Inhibition of JNK by SP600125 disrupts signaling pathways involved in Ameloblastin function, potentially affecting enamel formation and cellular interactions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a direct inhibitor of Ameloblastin, inhibiting phosphoinositide 3-kinases (PI3Ks). Its interference with the PI3K pathway influences Ameloblastin function, potentially impacting enamel formation and cellular interactions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a direct inhibitor of Ameloblastin, targeting the mitogen-activated protein kinase kinase (MEK) pathway by inhibiting MEK1 and MEK2. Its interference with the MAPK pathway influences Ameloblastin function, potentially impacting enamel formation and cellular interactions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a direct inhibitor of Ameloblastin, inhibiting p38 MAPK signaling. Its interference with the p38 MAPK pathway influences Ameloblastin function, potentially impacting enamel formation and cellular interactions. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK506, also known as Tacrolimus, is a direct inhibitor of Ameloblastin, acting as an immunosuppressive drug. Its inhibition of calcineurin disrupts signaling pathways related to Ameloblastin function, potentially impacting enamel formation and cellular interactions. | ||||||